

Press Release

SYGNIS AG announces global launch of TruePrime™ Single Cell WGA Kit V2

- SYGNIS is further executing on its launch program 2016
- TruePrime™ Single Cell WGA Kit V2 with significantly improved conditions for an expanded range of cell types and applications
- Product available through distribution partners and online shop

Madrid, Spain and Heidelberg, Germany, July 11th, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the global launch of TruePrime™ Single Cell WGA Kit V2 for whole genome amplification (WGA) from a broader range of cell types and an increased number of applications.

SYGNIS' TruePrime™ product family covers a series of kits for WGA without the need of random primers based on SYGNIS' proprietary TruePrime™ technology. This innovative DNA amplification technology is based on a combination of proteins working together to amplify smallest amounts of DNA in a very efficient way.

The newly launched TruePrime™ Single Cell WGA V2 Kit shows the same outstanding features as its predecessor including complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers and a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. The TruePrime™ Single Cell WGA V2 Kit shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and IonTorrent.

In addition to this, the kit provides new lysis conditions which allow WGA from a broader range of cell types and at the same time increase the number of applications. Lysis is a critical step in all amplification processes but especially in single cell analysis given the limited sample volumes. SYGNIS has developed an extensive project to define the best lysis reagents, buffers and conditions for a large number of different sample types. To keep tabs on the overall amplification process, the kit also includes human genomic DNA as an internal positive control.

"We are continuously expanding our product portfolio for DNA amplification and sequencing executing on our launching program scheduled for 2016 and we are looking forward to a row of exciting products still to come," **Pilar de la Huerta, CEO and CFO of SYGNIS** commented. "Our newly launched TruePrime™ Single Cell WGA V2 Kit, once again, proves our innovation strength and our commitment to develop products with superior features addressing urgent needs in molecular biology, especially in areas such as next generation sequencing and single cell analysis. We make good progress in establishing ourselves as a global leader in the development and commercialization of innovative tools for processing genetic information for a multitude of applications in fast

growing markets such as human genetics, oncology, molecular diagnostics and personalized medicine.”

For further information please contact:

SYGNIS AG

Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG

Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###